Chinook Therapeutics Stock Earnings Per Share
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Chinook Therapeutics fundamentals help investors to digest information that contributes to Chinook Therapeutics' financial success or failures. It also enables traders to predict the movement of Chinook Stock. The fundamental analysis module provides a way to measure Chinook Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Chinook Therapeutics stock.
Chinook |
Chinook Therapeutics Company Earnings Per Share Analysis
Chinook Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Chinook Therapeutics Earnings Per Share | (3.24) X |
Most of Chinook Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chinook Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Chinook Therapeutics has an Earnings Per Share of -3.24 times. This is 138.71% lower than that of the Biotechnology sector and 32.36% lower than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Chinook Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chinook Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics of similar companies.Chinook Therapeutics is currently under evaluation in earnings per share category among its peers.
Chinook Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (39.98) % | |||
| Current Valuation | 2.64 B | |||
| Shares Outstanding | 67.05 M | |||
| Shares Owned By Insiders | 2.19 % | |||
| Shares Owned By Institutions | 96.71 % | |||
| Number Of Shares Shorted | 2.88 M | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 27.90 X | |||
| Revenue | 6.13 M | |||
| Gross Profit | (135.08 M) | |||
| EBITDA | (164.2 M) | |||
| Net Income | (187.87 M) | |||
| Cash And Equivalents | 362.61 M | |||
| Cash Per Share | 5.76 X | |||
| Total Debt | 39.44 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 12.60 X | |||
| Book Value Per Share | 5.32 X | |||
| Cash Flow From Operations | (117.48 M) | |||
| Short Ratio | 3.43 X | |||
| Earnings Per Share | (3.24) X | |||
| Price To Earnings To Growth | (0.99) X | |||
| Target Price | 40.3 | |||
| Number Of Employees | 214 | |||
| Beta | 0.67 | |||
| Market Capitalization | 2.71 B | |||
| Total Asset | 574.08 M | |||
| Retained Earnings | (419.63 M) | |||
| Working Capital | 334.76 M | |||
| Z Score | 39.94 | |||
| Net Asset | 574.08 M |
About Chinook Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chinook Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |